Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

被引:17
作者
Tempfer, Clemens B. [1 ]
Hartmann, Franziska [2 ]
Hilal, Ziad [1 ]
Rezniczek, Guenther A. [1 ]
机构
[1] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany
来源
BMC CANCER | 2017年 / 17卷
关键词
Ovarian cancer; Intraperitoneal chemotherapy; Maintenance; Peritoneal carcinomatosis; PIPAC; Quality of life; Antineoplastic agents; Adverse effects; PHASE-II TRIAL; AEROSOL CHEMOTHERAPY; PRIMARY SURGERY; VINORELBINE; RECURRENT; OXALIPLATIN; GEMCITABINE; SURVIVAL; PIPAC;
D O I
10.1186/s12885-016-3004-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. Case presentation: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy. Conclusions: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.
引用
收藏
页数:6
相关论文
共 50 条
[21]   Pharmacological considerations regarding intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer [J].
de Bree, Eelco ;
Michelakis, Dimosthenis ;
Polioudaki, Hara ;
Anagnostopoulou, Elisabeth ;
Theodoropoulos, Panayiotis A. .
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (05) :1018-1028
[22]   Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer First Report of the HYPER-O Registry [J].
Helm, Cyril William ;
Richard, Scott D. ;
Pan, Jianmin ;
Bartlett, David ;
Goodman, Martin D. ;
Hoefer, Rick ;
Lentz, Sam S. ;
Levine, Edward A. ;
Loggie, Brian W. ;
Metzinger, Daniel S. ;
Miller, Brigitte ;
Parker, Lynn ;
Spellman, James E. ;
Sugarbaker, Paul H. ;
Edwards, Robert P. ;
Rai, Shesh N. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) :61-69
[23]   Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer [J].
Sugiyama, T ;
Kumagai, S ;
Nishida, T ;
Ushijima, K ;
Matsuo, T ;
Yakushiji, M ;
Hyon, SH ;
Ikada, Y .
ANTICANCER RESEARCH, 1998, 18 (4B) :2837-2842
[24]   A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer [J].
Suidan, Rudy S. ;
Clair, Caryn M. St. ;
Lee, Stephen J. ;
Barlin, Joyce N. ;
Roche, Kara C. Long ;
Tanner, Edward J. ;
Sonoda, Yukio ;
Barakat, Richard R. ;
Zivanovic, Oliver ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2014, 134 (03) :468-472
[25]   Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer [J].
Loek A. W. de Jong ;
Marie Lambert ;
Nielka P. van Erp ;
Lukas de Vries ;
Etienne Chatelut ;
Petronella B. Ottevanger .
Cancer Chemotherapy and Pharmacology, 2023, 91 :247-256
[26]   Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer [J].
Wang, Joyce Y. ;
Gross, Maya ;
Urban, Renata R. ;
Jorge, Soledad .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, :313-329
[27]   Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer [J].
de Jong, Loek A. W. ;
Lambert, Marie ;
van Erp, Nielka P. ;
de Vries, Lukas ;
Chatelut, Etienne ;
Ottevanger, Petronella B. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (03) :247-256
[28]   The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer [J].
Glennon, Kate ;
Mulligan, Karen ;
Carpenter, Kirsten ;
Mooney, Ruth ;
Mulsow, Jurgen ;
McCormack, Orla ;
Boyd, William ;
Walsh, Tom ;
McVey, Ruaidhri ;
Thompson, Claire ;
Ryan, Brid ;
Padfield, Katie ;
Murray, Patrick ;
Brennan, Donal J. .
GYNECOLOGIC ONCOLOGY REPORTS, 2021, 37
[29]   Intraperitoneal chemotherapy in ovarian cancer: An update [J].
Runowicz, Carolyn D. .
CANCER JOURNAL, 2008, 14 (01) :7-9
[30]   Intraperitoneal chemotherapy in the treatment of ovarian cancer [J].
Markman, M .
ANNALS OF MEDICINE, 1996, 28 (04) :293-296